In this episode, Erin Michos, MD, FACC, and Alison Bailey, MD, FACC discuss the CLEAR Outcomes primary prevention analysis focusing on bempedoic acid and its clinical implications. And per new FDA label:

NEXLETOL (bempedoic acid (an adenosine triphosphate-citrate lyase (ACL) inhibitor, is indicated:

• To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with:
• established cardiovascular disease (CVD), or
• at high risk for a CVD event but without established CVD. (1)
• As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

This podcast is part of the Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape grant initiative.

Educational grant support is provided by Esperion.

Related References:

1. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330:131-140.